FORMULATION AND EVALUATION OF CLOBETASOL-17-PROPIONATE-LOADED CARBOXYMETHYL CHITOSAN NANOPARTICLE

MAMTA YADAV; PANKAJ AGGARWAL; DEEPIKA YADAV; ANAND SINGH

doi:10.22159/ajpcr.2022.v15i9.45743

Authors

MAMTA YADAV Department of ???, School of Pharmacy and Medical Science Singhania University, Pacheri Bari, Jhunjhunu, Rajasthan, India.
PANKAJ AGGARWAL Department of ???, School of Pharmacy and Medical Science Singhania University, Pacheri Bari, Jhunjhunu, Rajasthan, India.
DEEPIKA YADAV Department of ???, School of Pharmacy and Medical Science Singhania University, Pacheri Bari, Jhunjhunu, Rajasthan, India.
ANAND SINGH Department of ???, School of Pharmacy and Medical Science Singhania University, Pacheri Bari, Jhunjhunu, Rajasthan, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i9.45743

Keywords:

Psoriasis, Skin, Topical drug delivery, Carboxymethyl chitosan, Nanoparticles

Abstract

Objective: Formulation and evaluation of clobetasol-17-propionate-loaded carboxymethyl chitosan nanoparticle. Psoriasis is a chronic skin disorder caused due to the autoimmune factors. It has a detrimental psychological and physiological impact on patients due to the emergence of apparent skin. The systemic therapy with anti-psoriatic drugs such corticosteroids, immunosuppressant, and gene suppressors causes severe side effects. As a result, increasing the effectiveness and safety of the aforementioned medicines when applied topically would be extremely useful in avoiding the side effects associated with the systemic route of administration.

Methods: Chitosan (CS) has not been widely used in the clinic applications but due to its limited solubility and poor mechanical characteristics. CS, on the other hand, is chemically changed to form carboxymethyl (CMC), which is soluble at both neutral and basic pH. Chemical modifications can also be used to attach different functional groups and control hydrophobic, cationic, and anionic properties. CMC is a promising carrier that might possibly traverse the thick scales of psoriatic skin since it is a penetration enhancer that allows drug diffusion through either the transcellular or paracellular pathways. Comparative study is done using CMC as a polymer and CD as a polymer.

Results: CP-loaded CMC nanoparticles show better result results than CP-loaded CD polymer.

Conclusion: Clobetasol-17-propionate-loaded carboxymethyl chitosan nanoparticle shows better results with improved solubility.

Downloads

Download data is not yet available.

References

Hardy A, Seguin C, Brion A, Lavalle P, Schaaf P, Fournel S, et al. β-cyclodextrin-functionalized chitosan/alginate compact polyelectrolyte complexes (CoPECs) as functional biomaterials with anti-inflammatory properties. ACS Appl Mater Interfaces 2018;10:29347-56.

Prabaharan M. Review Paper: Chitosan derivatives as promising materials for controlled. Drug Delivery. J Biomater Appl 2008;23:5-36.

Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010;62:3-11.

Diebold Y, Jarrín M, Sáez V, Carvalho EL, Orea M, Calonge M, et al. Aslocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007;28:1553-64.

Gupta KC, Ravi kumar MN. An overview on chitin and chitosan applications with an emphasis on controlled drug release formulations. J Macromol Sci Part C Polym Rev 2000;40:273-308.

Wang Y, Li B, Xu F, Han Z, Wei D, Jia D, et al. Tough magnetic chitosan hydrogel nanocomposites for remotely stimulated drug release. Biomacromolecules 2018;19:3351-60.

Liu D, Li J, Pan H, He F, Liu Z, Wu Q, et al. Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin. Sci Rep 2016;6:28796.

Ammar M, Souissi-Bouchlaka C, Gati A, Zaraa I, Bouhaha R, Kouidhi S. Psoriasis: physiopathology and immunogenetics. Pathol Biol (Paris) 2014;62:10-23.

Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999;140(Suppl 54):1-7.

Liu Y, Krueger JG, Bowcock AM. Psoriasis: Genetic associations and immune system changes. Genes Immun 2007;8:1-12.

Ansel JC, Tiesman JP, Olerud JE, Krueger JG, Krane JF, Tara DC. Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J Clin Invest 1993;92:671-8.

Viac J, Palacio S, Schmitt D, Claudy A. Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes. Arch Dermatol Res 1997;289:158-63.

Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.

Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: An update on developing targeted therapies. Dis Model Mech 2012;5:423-33.

Wrone-Smith T, Nickoloff BJ. Dermal injection of immune cytes induces psoriasis. J Clin Invest 1996;98:1878-87.

Austin LM, Coven TR, Bhardwaj N, Steinman R, Krueger JG. Intraepidermal lymphocytes in psoriatic lesions are activated GMP- 17(TIA-1)+CD8+CD3+CTLs as determined by phenotypic analysis. J Cutan Pathol 1998;25:79-88.

McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23.

McManus R. Mechanisms of steroid action and resistance in inflammation and diseas. J Endocrinol 2003;178:1-4.

Hebbar PB, Archer TK. Chromatin remodeling by nuclear receptors. Chromosoma 2003;111:495-504.

McKay LI. Cidlowski JA. Molecular control of immune/inflammatory responses: Interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999;20:435-59.

De Bosscher K, Berghe WV, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappa B or activator protein-1:Molecular mechanisms for gene repression. Endocr Rev 2003;24:488-522.